JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα-Reference-Cited by-同舟云学术

JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα

Published:2013-08-22 Issue:8 Volume:122 Page:1464-1477
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Hasan Salma¹,Lacout Catherine¹,Marty Caroline¹,Cuingnet Marie¹,Solary Eric¹,Vainchenker William¹,Villeval Jean-Luc¹

Affiliation:

1. Institut National de la Santé et de la Recherche Médicale, U.1009, Villejuif, France; Institut Gustave Roussy, Villejuif, France; and Université Paris XI, Villejuif, France

Abstract

Key Points JAK2V617F amplifies in mouse early hematopoietic cells, giving them a proliferative advantage through high cell cycling and low apoptosis. IFNα prevented myeloproliferative neoplasm development by specifically inhibiting JAK2V617F cells at an early differentiation stage.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/8/1464/1374437/1464.pdf

Reference50 articles.

1. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.;James;Nature,2005

2. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.;Baxter;Lancet,2005

3. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.;Levine;Cancer Cell,2005

4. A gain-of-function mutation of JAK2 in myeloproliferative disorders.;Kralovics;N Engl J Med,2005

5. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.;Lacout;Blood,2006

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis;Leukemia;2024-07-18

2. Increased CXCL10 (IP-10) is associated with advanced myeloproliferative neoplasms and its loss dampens erythrocytosis in mouse models;Experimental Hematology;2024-07

3. Exacerbation of thromboinflammation by JAK2 V617F mutation worsens the prognosis of cerebral venous sinus thrombosis;Blood Advances;2024-06-25

4. Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F–positive myeloproliferative neoplasms;Blood;2024-06-13

5. Mathematical modelling, selection and hierarchical inference to determine the minimal dose in IFNα therapy against myeloproliferative neoplasms;Mathematical Medicine and Biology: A Journal of the IMA;2024-06